Friday, October 30, 2026

EUR/GBP Jumps By 1% In The Last 10 Sessions

EUR/GBP Jumps By 1% In The Last 10 Sessions

(VIANEWS) - EUR/GBP (EURGBP) has been up by 1.01% for the last 10 sessions. At 20:07 EST on Thursday, 29 June, EUR/GBP (EURGBP) is $0.86.

EUR/GBP's yearly highs and lows, it's 3.285% up from its 52-week low and 6.735% down from its 52-week high.

Volatility

EUR/GBP's last week, last month's, and last quarter's current intraday variation average was a positive 0.04%, a negative 0.04%, and a positive 0.24%, respectively.

EUR/GBP's highest amplitude of average volatility was 0.26% (last week), 0.26% (last month), and 0.24% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/GBP's Forex is considered to be oversold (<=20).

Previous days news about EUR/GBP (EURGBP)

  • Eur/gbp price analysis: portrays inverted h&s as speeches from boe’s bailey, ecb’s lagarde loom. According to FXStreet on Wednesday, 28 June, "In a case where the EUR/GBP breaks the 0.8520 level, a quick fall toward the 0.8500 threshold can't be ruled out.", "Following that, the late May swing high of around 0.8720 may prod the EUR/GBP bulls during the run-up aiming for the theoretical target of the inverse H&S, namely around 0.8730."
  • Gbp/usd might find some support near 1.2600, eur/gbp could easily drift back under 0.8600 – ING. According to FXStreet on Thursday, 29 June, "Until then GBP/USD might find some support near 1.2600 and EUR/GBP could easily drift back under 0.8600."

More news about EUR/GBP (EURGBP).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com